NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 877.4 DKK | +1.22% |
|
+1.58% | +26.04% |
| Apr. 25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
Presenter SpeechMads Thomsen (Executives)We are approaching 7:00, and we are very excited to h...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
866.8
DKK
Average target price
904.2
DKK
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.04% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.94% | 233B | |
| +5.26% | 201B | |
| -10.10% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B | |
| +0.70% | 123B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S Presents at American Diabetes Association 78th Scientific Sessions, Jun-24-2018 07
